The therapeutic effects of saccharolytic and proteolytic enzymes were investigated in models of IgA nephropathy. Mesangial glomerulonephritis was induced in mice by intravenous injection of preformed soluble immune complexes of dextran sulfate and either IgA (J 558) or IgM (MOPC 104 E) anti-dextran MAb (passive model) or by immunization with DEAE dextran (active model). In the passive model, only 30-40% of dextranase-treated mice given IgA or IgM immune complexes had mesangial Ig or dextran deposits, compared with 100% of saline-treated controls (P less than 0.01). There was no significant difference in mice given only protease. In the active model, dextranase and protease separately each reduced glomerular dextran and C3 deposits, and hematuria (P less than 0.01). Dextranase also reduced the glomerular IgA deposits (20 vs. 100% of saline-treated mice) and the frequency and severity of mesangial matrix expansion (both P less than 0.02), but did not reduce the modest IgG or IgM codeposits. Protease reduced IgG and IgM deposits, proteinuria and mesangial hypercellularity compared with saline (P less than 0.02), but did not diminish IgA, and had no effect on mesangial matrix expansion. The combination of dextranase plus protease attenuated all components of glomerular injury as judged by clinical and pathological parameters, but inactivated dextranase plus inactivated protease had no effect on any parameter. We conclude that enzymatic digestion of […] 
Introduction
Immune complexes play a central role in initiation and propagation of glomerulonephritis. Reasoning that enzymatic dissolution of immune complexes could diminish their mass thin glomeruli and thereby attenuate disease, we previously dem-onstrated that parenteral injection of proteolytic enzymes capable of digesting both the antigen and antibody components of immune complexes can reduce the amount of complexes in glomeruli of both rats and mice with passive serum sickness glomerulonephritis (1) . Similar observations were subsequently reported in rabbits by Steffen and Menzel (2) . When such therapy was extended to rats with passive Heymann nephritis, we observed the prevention and even reversal of proteinuria, the clinical hallmark of this model of membranous glomerulonephritis (3) . Active Heymann nephritis has also been effectively treated with intravenous pepsin (4) . Recently, we showed that protease therapy can reverse not only severe proteinuria but also the hyperlipidemia associated with the nephrotic syndrome in a model of active serum sickness induced in rats by immunization with cationic bovine gammaglobulin (5) .
We considered whether enzyme therapy could be ofbenefit as well in proliferative glomerulonephritis characterized clinically by hematuria, and to what extent cleavage ofantigen and antibody separately by different classes of enzyme would be effective. These questions can be approached in models of IgA nephropathy. IgA nephropathy, an immune complex glomerulonephritis, is the most prevalent form of glomerulonephritis worldwide (6, 7) . It typically manifests clinically as hematuria, which may be accompanied by proteinuria, renal insufficiency, and hypertension. IgA nephropathy is recognized pathologically by a proliferation of cells and expansion of matrix within the glomerular mesangium, associated with electron dense mesangial immune deposits, which by immunofluorescence contain IgA and C3 and lesser amounts of IgG and IgM (6, 7) .
A number of models of IgA nephropathy are available in rats and mice, each emphasizing different aspects of the disease (8) . Among these, chronic immunization of mice with dextran elicits a glomerulonephritis that closely resembles clinically and pathologically typical cases of IgA nephropathy in humans (9-1 1) . We considered this model ofIgA nephropathy an ideal system for our purposes because of its clear, objective clinical and pathologic signs of disease and because the polysaccharide antigen and protein antibody components of the immune complexes involved can be independently cleaved by different classes of enzyme. Use of a saccharidase to dissolve glomerular immune complexes containing polysaccharide antigen in vivo also serves as an additional control to ensure that our prior success with enzyme therapy of experimental glomerulonephritis was not due to some nonspecific systemic proteolytic action. MO ) and murine monoclonal IgA anti-a I 6 glycoside (J558; Litton Bionetics, Kensington, MD) or IgM anti-al 3 glycoside (MOPC 104 E; Litton Bionetics) were prepared at threefold antigen excess (26. 5 ,g dextran/mg J558; 22.0 ,gg dextran/mg MOPC 104 E). Complexes containing 3 mg antibody were injected into 20-g male Swiss-Webster mice (Charles River Breeding Laboratories, Lexington, MA) via tail vein (9) . 1 h later, after maximal deposition of complexes, mice were injected intraperitoneally with five doses of either saline, 0.1 mg dextranase, or 0.05 mg nagarse (subtilisin) plus 0.1 mg chymopapain, at 10-min intervals. These doses were nontoxic in pilot studies. All enzymes were purchased from Sigma Chemical Co. Mice were killed 1 h after the last enzyme injection. The dextranase had < 5 millicaseinolytic units per mg protein, as opposed to the proteases, which had 2,000-7,000 mU/mg protein (12) .
Induction and treatment of active IgA nephropathy. 35-g male Swiss-Webster mice (Charles River Laboratories) were divided into five groups: 4 groups (37 mice total) were given 1 mg i.p. 500 kD DEAE-dextran (Sigma Chemical Co.) in PBS, pH 7.4, on days 1, 7, and 10 followed by injections of 1 mg i.v. ofdextran thrice weekly until day 75, for a total of 30 mg (10, 11) . Group 5 (control, 10 mice) received saline. Randomly selected immunized mice were then treated with either dextranase (0.5 mg i.v.), chymopapain plus nagarse (0.38 mg plus 0.18 mg i.p.), a combination of dextranase intravenously and protease intraperitoneally, or saline, twice a day for 5 d. The enzyme doses were the maximum that did not elicit histological or clinical evidence of toxicity in pilot studies. After the last enzyme injection, all mice were placed in individual metabolic cages and urine was collected for 24 h. Urine was tested with Hemastix and Albustix (Ames Division, Miles Laboratories, Elkhart, IN) and centrifuged. Supernatants were assayed for protein by turbidimetry in 3% sulfosalicylic acid (3) . Sediments were used for microscopic determination of the number of erythrocytes in three high-power (40X) fields for each mouse. Mice were subsequently killed under ether anesthesia and blood was collected from the aortas. Serum creatinine was measured by Jaffe's picric acid method (3) .
Induction ofactive IgA nephropathy and treatment with inactivated enzymes. 24 mice were immunized with dextran as described above; another 8 mice served as controls. After completion of immunization, a pretreatment urine collection (initial) was performed, and hematuria and proteinuria were determined (see below). The 21 hematuric and the 3 nonhematuric mice were separately randomly allocated to 3 groups (8 mice per group), which were treated either with saline, a mixture of protease and dextranase, or a mixture of inactivated protease and inactivated dextranase (see below). Saline and active enzymes were administered as described above. Inactivated enzymes were given at the same mass, concentration, route, and times as the active enzymes. There were no differences among the immunized groups with respect to severity or frequency of initial hematuria or proteinuria. After 5 d of treatment, all mice were housed in individual metabolic cages for urine collection and killed for morphologic and serologic study as (14, 15) . After bubbling nitrogen through the solutions, DTT (International Biotechnologies, Inc., New Haven, CT) was added to a final concentration of 30 mM. The mixture was then incubated at 37°C for 3 h and iodoacetamide was added to a final concentration of 33 mg/ml; an equal mass of solid Tris base was added simultaneously to prevent rapid pH change (15) . The pH of the mixture was adjusted to 8.0 with 1 M Tris base. After 30 min at 4°C, the solution was exhaustively dialyzed against PBS. Active (0-500 ,g/ml) and inactive (0-1,500 ,g/ml) chymopapain at varying concentrations were incubated at 25°C for 60 min with N-a benzoyl-DL-arginine p-nitroanilide (Sigma Chemical Co.) and active (0-500 ,ug/ml) and inactive (0-1,500 gg/ml) nagarse at varying concentrations were incubated with N-acetyl-L-alanine p-nitroanilide (Sigma Chemical Co.) at 250C for 60 min. The chromogenic peptide substrates were first dissolved at 43.5 mg/ml in DMSO (Sigma Chemical Co.) and then diluted 1:10 in PBS just before enzyme addition. The change in the optical density at 405 nm per minute, divided by the micromolar extinction coefficient ofp-nitroaniline (5.495 X Io-') was taken as the enzymatic activity. Active chymopapain had a specific activity of 0.957 U/mg, whereas inactivated chymopapain had 0.096 U/mg (90% inhibition). Active nagarse had a specific activity of 1.67 U/mg, whereas inactivated nagarse had < 0.034 U/mg (98% inhibition).
Statistical analysis. Count and semiquantitative data were compared among groups with the chi-squared test with the Fisher-Yates correction always applied. Quantitative data were compared by analysis of variance, with multiple inferences by Fisher's protected t test.
Results
Passive IgA nephropathy model All 10 mice injected with soluble preformed IgA-dextran immune complexes and sham-treated with saline had granular mesangial deposits of IgA and dextran, but no detectable IgM or IgG; in contrast, only 3 of 10 mice given identical doses of IgA immune complexes but treated with dextranase had IgA deposits ( Fig. 1 A) (X2 = 7.9; P < 0.01 vs. saline-treated mice) and only 4 mice had detectable dextran deposits (X2 = 6.0; P < 0.02 vs. saline). Protease treatment did not significantly alter either IgA or dextran deposits. Among 10 mice given soluble preformed IgM-dextran immune complexes and treated with saline, all 10 had granular mesangial IgM and dextran ( Fig. 1  B) , without IgA or IgG. Again, dextranase treatment significantly reduced mesangial immunoglobulin (IgM) and dextran (both positive in only 4 of 10 mice) (X2 = 6.0; P < 0.02 vs. saline-treated mice). Protease treatment had no effect. No group exhibited significant C3, and the mild increase in PASpositive mesangial matrix seen in all mice given immune complexes did not vary among the groups. None of eight normal control mice had any IgA, IgM, or dextran deposits. Active IgA nephropathy model Morphology. Immunofluorescence microscopy (Figs. 2 and 3) revealed bright granular mesangial staining for IgA in all 10 dextran-immunized mice treated with saline; IgM was present in 9 of these mice and IgG in 8, both with parallel mild to moderate staining intensity in the same distribution, appreciably less intense than the IgA deposits. 6 of these 10 mice had moderately intense mesangial C3 as well. Moderate to intense staining for dextran was demonstrable by immunoperoxidase in all 10 immunized mice treated with saline. None of the nonimmune, age-matched control mice had deposits of Ig, C3, or dextran (all X2 2 6; P < 0.02). By light microscopy (Table I , Fig. 4) , there was generally moderate mesangial hypercellularity and moderate to marked expansion of mesangial matrix in all immunized saline-treated mice compared with nonimmune controls (X2 = 16.2; P < 0.001). Mean mesangial matrix area in saline-treated nephritic mice was higher than in controls, whether normalized for total glomerular area or not (both P < 0.001). Likewise, the number of nuclei was 60% higher in nephritic mice versus controls (P < 0.001 whether normalized for glomerular area or not). No extracapillary or endocapillary proliferation was observed and changes were confined to the mesangium. Tubular basement membranes of immunized mice were expanded with PAS-positive material as well, and occasional vacuoles were evident in glomerular and tubular cells (Fig. 4) , but no tubulointerstitial infiltration or fibrosis was evident. Ultrastructurally, immunized mice had numerous, variably sized but generally large vacuoles containing inclusions of variable density in podocytes, endothelial cells, and mesangial cells, and electron-dense and -lucent deposits in subendothelial and mesangial sites (not shown) similar to those previously described (1 1 PAS-positive material in mesangial matrix (Fig. 4 , Table I ) and tubular basement membrane compared with saline-treated immunized mice; only 2 dextranase-treated mice had more than a trace increase in mesangial matrix compared with all 0 treated with saline (X2 = 10.2; P < 0.005), and the mean mesangial area in dextranase-treated mice was not different from normals, but 36% less than in saline-treated nephritic mice (P < 0.001). Hematuria was also significantly reduced by dextranase treatment (Table II) ; only 6 of 1O mice had any hematuria and none of 10 had more than five RBCs per high-power field whereas all 1O saline-treated mice had more than nine red cells per high-power field (X2 = 16.2; P < 0.001). There was no significant difference between dextranase and saline treatment in regard to proteinuria and serum creatinine (Table II) . Protease therapy. Protease treatment of active IgA nephropathy significantly reduced the frequency of the mild to moderate mesangial deposits of both IgG (2 of 9 mice) and IgM (1 of 9 mice) compared with saline-treated immunized mice (8 of 10 and 9 of 10, respectively) (X2 = 4.2, 8.9; P < 0.05, 0.01) (Figs. 2 and 3) . Although only 1 of 9 protease-treated 718 mice had mesangial C3, this was not significantly different from the 6 of 10 C3 positive saline-treated mice (X2 = 3.0). Protease by itself was ineffective at reducing glomerular IgA. Protease reduced the incidence of dextran deposits (four of nine mice) relative to saline treatment (X2 = 4.9; P < 0.01). The frequency distribution of mice with respect to mesangial matrix expansion in protease-treated mice was intermediate between mice treated with saline and dextranase (Fig. 4 , Table  I ), but the difference in frequency between either of these groups and protease-treated mice was not significant (X2 = 1.8 and 2.5, respectively). Mesangial matrix area in proteasetreated mice did not differ from that in saline-treated mice. Protease reduced the extent of mesangial cellularity by 35% compared with saline-treated mice (P < 0.001), a level not significantly different from controls. The incidence of semiquantitative scores showed a trend towards milder prolifera- Figure 4 . Light micrographs. Representative glomeruli from normal control mice (A) and dextran-immunized mice treated with combined dextranase plus protease (B), dextranase (C), protease (D), or saline (E) reveal that saline-treated mice (E) had moderate to marked expansion of mesangium by PAS-positive matrix accumulation, and generally severe mesangial hypercellularity as opposed to the normal animals (A), with only two to three nuclei per mesangial area. Combined therapy (B) and dextranase alone (C) reduced matrix expansion and mesangial hypercellularity, whereas protease alone (D) reduced only cellularity. Note also that vacuoles (arrows) are present in glomerular cells in mice given saline (E), but are not conspicuous in other groups. See also tion, but the difference was not significant compared to either saline or control groups. Protease therapy significantly reduced hematuria relative to mice treated with saline; only 2 of the 9 protease-treated mice had more than five red cells per high-power field versus all 10 of the saline treated mice (X2 = 9.2; P < 0.01), and 3 of the 9 protease-treated mice had no increase in urinary erythrocytes compared to normal controls (Table II) . Protease also significantly reduced proteinuria to 0.91±0.20 mg/24 h compared with 1.51±0.23 mg/24 h in saline-treated nephritic mice (t = 2.3; P < 0.05). Although protease reduced serum creatinine levels relative to saline-treated mice, the difference was not significant, and protease-treated mice had significantly higher serum creatinine (0.26±0.02 mg/dl) than normal control mice (0.15±0.02 mg/dl; t = 2.4; P < 0.05).
Combined dextranase andprotease therapy. Mice rendered nephritic by immunization with dextran and treated with both dextranase and protease had dramatic reductions in glomerular IgA, IgG, IgM, and C3 (Figs. 2 and 3) . Only 1 mouse evidenced glomerular Ig (all three isotypes), versus 8-10 mice of the 10 given saline (X2 > 5.6; P < 0.01), and no treated mouse had glomerular C3 as opposed to 6 of the 10 given saline (X2 = 5.0; P < 0.025). Significantly fewer mice given combined therapy had dextran deposits (2 of 8) compared with the nephritic mice treated with saline (10 of 10; x2 = 8.13; P < 0.01). Light microscopy likewise revealed significant decreases in both the mesangial matrix accumulations and hypercellularity seen in saline-treated immunized mice (P < 0.01) as judged by both distribution of semiquantitative scores and quantitative morphometry (Table I, Fig. 4 ). Combined protease and dextranase treatment did not influence the intracellular vacuoles or deposits seen ultrastructurally in saline-treated immunized mice.
Combined enzyme therapy was more effective at reducing hematuria than either protease or dextranase alone (Table II) ; only 1 mouse ofthe 8 treated with the combined enzymes had hematuria exceeding normal controls, as opposed to all 10 saline-treated mice (X2 = 10.9; P < 0.001). Proteinuria was significantly less in mice given combined enzymes (0.63±0.14 mg/24 h) than in nephritic mice treated with saline (1.51±0.23 mg/24 h; t = 3.3; P < 0.01), reaching the levels in normal controls (0.83±0.17 mg/24 h). Combined therapy, like therapy with protease alone or dextranase alone, did not significantly reduce serum creatinine. Dependence oftherapeutic effect on enzymatic activity. To determine whether the efficacy of the enzymes resides with their lytic capability or with some other effect, a third experiment was performed. In this experiment, mice immunized with dextran developed hematuria and proteinuria as already described. Once again, hematuria and proteinuria persisted after 5 d of saline therapy, but were significantly reduced after 5 d of therapy with a combination of protease and dextranase (active enzymes, Table III ). In contrast, the combination of inactivated protease and inactivated dextranase (inactive enzymes, Table III) had no significant effect, and mice treated with inactive enzymes showed significantly more hematuria and proteinuria than mice treated with active enzyme or normal control mice. Active but not inactive enzymes significantly reduced glomerular immune deposits of IgA, IgG, IgM, and C3, and mesangial hypercellularity and matrix expansion evident by light microscopy (Table III) .
Discussion
The results presented here confirm earlier observations ( (16) (17) (18) (19) , all ofwhom used excess antigen to solubilize glomerular immune deposits in systems where the antigen was known. Advantages of using enzymes rather than excess antigen to dissolve glomerular immune complexes are that knowledge of the relevant antigen is not required to achieve a therapeutic effect and that the antibody component of immune complexes, at least, will always be subject to proteolysis. Although not an issue in experimental glomerulonephritis where the antigen is known, there are few instances of glomerulonephritis in humans in which the antigen is known. We believe that nontoxic doses of exogenous enzymes potentially can be used to dissolve glomerular immune complexes in spontaneous human glomerulonephritis, a category of disease for which there is currently no effective therapy. The studies described here further support this concept, and additionally offer hope that in cases where the culprit antigen includes a polysaccharide component, even if of unknown identity, combination therapy with saccharolytic enzymes may be more effective than protease therapy alone. Another use of the kind of therapeutic maneuvers used in this study is to probe the role of pathophysiologic mechanisms and specific mediators operative in glomerulonephritis. Along these lines, dextranase appeared to reduce mesangial matrix expansion more effectively than protease, whereas protease was more effective at reducing hypercellularity. These data suggest that the IgA or antigen components removed by dextranase are more closely coupled to matrix expansion, but IgG or IgM components removed by protease are more closely linked to proliferation. These considerations provide the basis for a testable hypothesis relating different components of glomerular immune deposits and the inflammatory response.
The differences in the effects of protease versus dextranase given individually are of interest. Although IgA may be more resistant to proteolysis than IgG or IgM, the failure of dextranase to diminish deposits of IgG and IgM in the active model is surprising. Indeed, if dextran were the only antigen involved in the deposited immune complexes, IgG and IgM would likely be dislodged effectively by the dextranase. In the passive model, induced by injection of immune complexes of dextran and IgM anti-dextran antibody in pure form, IgM deposits were reduced by dextranase. Hence, it is possible that the persistent IgG and IgM codeposits in the active model represent antibody specific for some antigenic component other than dextran, perhaps a polypeptide sensitive to protease but not dextranase. Anti-dextran antibody of all three major isotypes is demonstrable in sera of immunized mice, but we cannot exclude participation of other antigens. Indeed, we Whatever the detailed composition of the deposits, it is clear that protease and dextranase, particularly in combination, can reduce immune deposits and functional and morphologic expression of glomerular injury in these models of IgA nephropathy. Hematuria, mesangial matrix expansion, and cell proliferation thus join proteinuria and quantity of immune deposits as disease parameters which can be attenuated by systemic administration of nontoxic doses of enzymes capable of cleaving immune complexes. This approach may prove useful in probing the relation between structure and function and between stimulus and response in glomerulonephritis, and holds promise as a future therapeutic strategy as well.
